Given that ADCC is a key mechanism for the antitumor activity of inetetamab16, 55, we need to consider the role of the interaction between inetetamab and immune cells in killing tumor cells in addition to the AKT/Nrf2/ROS/NLRP3/caspase-1/GSDMB axis when studying the mechanism by which cisplatin and inetetamab exert synergistic antitumor effects. Here, NLRP3 is linked to neoplasm.